agilon health (AGL) Stock Price, News & Analysis

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for agilon health in the last year. There are currently 1 sell rating, 11 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGL, but not buy additional shares or sell existing shares.
View AGL analyst ratings or view top-rated stocks.

16 analysts have issued 12-month price targets for agilon health's stock. Their AGL share price targets range from $5.00 to $18.00. On average, they expect the company's stock price to reach $9.73 in the next twelve months. This suggests a possible upside of 118.2% from the stock's current price.
View analysts price targets for AGL or view top-rated stocks among Wall Street analysts.

agilon health's stock was trading at $12.55 at the beginning of 2024. Since then, AGL stock has decreased by 64.5% and is now trading at $4.46.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AGL earnings forecast.

agilon health, inc. (NYSE:AGL) posted its earnings results on Tuesday, February, 27th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.13. The firm had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.02 billion. agilon health had a negative net margin of 5.76% and a negative trailing twelve-month return on equity of 21.74%. The company's revenue for the quarter was up 71.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.14) EPS.

ETFs with the largest weight of agilon health (NYSE:AGL) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), iShares U.S. Healthcare Providers ETF (IHF), Fidelity Disruptive Medicine ETF (FMED), Texas Capital Texas Equity Index ETF (TXS), Fidelity Fundamental Large Cap Growth ETF (FGRO) and Renaissance IPO ETF (IPO).RiverNorth Patriot ETF (FLDZ).

agilon health issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $6.4 billion-$6.5 billion, compared to the consensus revenue estimate of $6.3 billion.

agilon health (AGL) raised $1 billion in an initial public offering (IPO) on Thursday, April 15th 2021. The company issued 46,600,000 shares at a price of $20.00-$23.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Deutsche Bank Securities and Wells Fargo Securities served as the underwriters for the IPO and William Blair, Truist Securities and Nomura were co-managers.

agilon health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Capital LLC (0.05%) and Counterpoint Mutual Funds LLC (0.02%). Insiders that own company stock include Benjamin Kornitzer, Benjamin Shaker, Cd&R Investment Associates Ix,, Clay Richards, Glenn Sobotka, Jeffrey A Schwaneke, Joan Danieley, John William Wulf, Michael L Smith, Steven Sell, Theodore Halkias, Timothy Gertsch and Veeral Desai.
View institutional ownership trends.

Shares of AGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.